Navigation Links
NewCardio Leadership to Present Two Abstracts at ISCE Conference
Date:3/31/2009

Company to Present Data on the Use of its Proprietary Technology to Provide Accurate, Fully Automated ECG Analysis for Drug Cardiac Safety at 34th Annual ISCE Meeting

SANTA CLARA, Calif., March 31 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that senior leadership will present clinical data from two abstracts and discuss applications for its proprietary technology at the 34th Annual International Society for Computerized Electrocardiology (ISCE) Conference. The conference is scheduled from April 23-27, 2009 in Panama City Beach, Florida.

The Society is devoted to the advancement of electrocardiography through the application of computer methods and its annual scientific conference brings together scientists, clinicians, engineers and policy makers working in the field. Dr. Branislav Vajdic, NewCardio's Chief Executive Officer and Dr. Bosko Bojovic, Co-Founder and Senior Technology Consultant, will present at this conference. Visit http://www.isce.org/generalinfo.html for more information.

Drs. Vajdic and Bojovic will present two abstracts at the conference:

  • "Human Overread of Semi-Automated QT Measurements May Adversely Affect Final Results In Cardiac Safety Studies," authored by Drs. Branislav Vajdic, Ihor Gussak (NewCardio's Chief Medical Officer), Bosko Bojovic, and Samuel George (NewCardio's Senior Consultant). This study presents data showing that human adjustment of computer-generated ECG measurements may lead to unexpected distortions in key parameters that affect drug safety assessment.
  • "End of T Wave Determination by Polynomial Curve Fitting on a Vector Magnitude Lead," authored by Drs. Bosko Bojovic, Ljupco Hadzievski, Ihor Gussak, Samuel George and Branislav Vajdic. This presentation will feature a technical summary of NewCardio's proprietary automated methods for accurate and precise time interval measurements in ECGs from cardiac safety studies. Such measurements are the key indicators of potential drug effects on the heart. NewCardio's approach, covered by two recent patent applications filed in the U.S. and under the international Patent Cooperation Treaty, provides a novel, baseline-independent, iterative computer process that has been extensively validated in recent retrospective drug safety trials.

Branislav Vajdic, PhD, NewCardio's Chief Executive Officer, commented, "NewCardio management is excited to discuss our findings and elaborate on how we can bring new levels of efficiency and accuracy to clinical drug trials with our fully automated QTinno(TM) solution. Unlike other approaches, which are limited due to the reliance on the two-dimensional methodology, NewCardio's proprietary technology matches the most rigorous manual readings from highly trained cardiologists in a fully automated manner. The ISCE Conference is an excellent opportunity to discuss our novel technology with recognized industry leaders in attendance, and explore the various applications we will be aggressively pursuing in the coming months and years."

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0

    Investor Contact:
    Hayden IR
    Jeff Stanlis
    Partner and Vice President of Communications
    (602) 476-1821
    jeff@haydenir.com


'/>"/>
SOURCE NewCardio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Vincent W. Renz Joins NewCardio as President
2. NewCardio Announces Positive Results From Third Clinical Validation Study
3. Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts
4. Evalve Expands Executive Leadership Team
5. BBK Worldwide Celebrates 25th Anniversary of Industry Leadership Through Innovation in Patient Enrollment
6. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
7. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
8. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
9. RenalGuard(R) Pilot Safety Clinical Trial Data to be Presented at ACC 2009
10. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
11. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced ... President and Chief Executive Officer (CEO) and member of the ... Richard Love , interim President and CEO who will ... Craig has over 20 years of experience in hematology, oncology ... Europe . "On behalf of CTI BioPharma,s ...
(Date:2/27/2017)... The Dutch secure mobile phone ... at the security level RESTRICTED. The solution thus meets the ... the communication of classified information. ... Sectra and Samsung have a strategic ... solution. Sectra Tiger/R is developed by Sectra under guidance from ...
(Date:2/24/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Wireless Health ... over the next decade to reach approximately $330.5 billion by 2025. ... for all the given segments on global as well as regional ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... This ... became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p ... ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for the ...
(Date:2/26/2017)... ... ... IndustryArchive.Org . is announcing a new way for B2B Sellers to promote ... for B.A.N.T. quality sales leads based on the Sellers decision to purchase a sales ... B2B buyers are controlling the sales process via the Internet and that ad targeting ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports ... a study released today at the 1st Pan American Parkinson’s and Movement Disorders ... be effective in improving cognitive function in PD patients. This study, led by ...
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, expert standing desk solution ... advantages built into the home office sit stand solution are bold colors, a ... gain the benefits embedded in the TaskMate Go are available 24/7 through HealthPostures' ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... education, networking and recognition opportunities as well as advocacy for the state and ... NJ on February 23. The Council's Innovation Forecast event highlights innovation throughout ...
Breaking Medicine News(10 mins):